Financial conflicts of interest were present in the majority of cancer research reviewed in a study published July 15 in the Journal of the National Cancer Institute.
Researchers from New Haven, Conn.-based Yale University reviewed 36 studies published since 2015 to assess the prevalence of industry ties. Studies included in the analysis covered six areas: clinical trials, FDA meeting speakers, academic medical leaders, patient advocacy organizations, clinical guideline authors and practicing oncologists.
Here are three notes from the study:
- Financial conflicts of interest were present in 36.8% to 89% of cancer clinical trials, 65% to 92.1% of FDA meeting speakers and 76% to 100% of academic medical leaders.
- Financial conflicts of interest were present in 56% to 98.1% of patient advocacy organizations, 46.4% to 98.4% of clinical guideline and pathway authors and 24.7% to 100% of practicing oncologists.
- Industry sponsorship was found in 69% of clinical trials and among 61% of practicing oncologists, pooled across eligible studies.
Read the full study here.
